Risperdal

Nursing homes face federal False Claims Act charges for allegedly overmedicating residents with antipsychotics, other drugs

Nursing homes face federal False Claims Act charges for allegedly overmedicating residents with antipsychotics, other drugs

By

Two California nursing homes routinely overmedicated residents with antipsychotics and other drugs "for the convenience of management," according to federal charges announced Wednesday by the Office of Inspector General.

Antipsychotic use tied to acute kidney injury, increasing pressure on nursing home reduction efforts

By

Older people who take antipsychotic medications are at a markedly increased risk of acute kidney injury, according to newly published research findings out of Canada. The study further supports ongoing efforts to reduce the number of nursing home residents on these drugs.

Law firm pursues Risperdal link to gynecomastia

Following research that indicates a possible link between gynecomastia and use of Risperdal, a law firm says it is continuing to offer legal consultations to those who developed the condition.

Glaxo will stop paying doctors for speaking gigs in industry-leading change

By

Pharmaceutical giant GlaxoSmithKline will stop paying healthcare professionals to speak about its products, and will alter other marketing and compensation practices that are common in the industry but derided by critics, the company announced Tuesday.

A tough retirement nest egg, the whistle-blowing way

A tough retirement nest egg, the whistle-blowing way

By

Two big reactions hit me when news of Johnson & Johnson's $2.2 billion Risperdal settlement with the government landed this week. First, J&J probably made a lot more than it's paying out and, second, some individual probably is going to cash a nice paycheck for bringing it all to light.

Johnson & Johnson to pay $2 billion in settlement over antipsychotic drugs in nursing homes

Johnson & Johnson to pay $2 billion in settlement over antipsychotic drugs in nursing homes

By

Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes, the U.S. Department of Justice announced Monday. The agreement is one the largest ever of its kind, and will also settle charges that the companies paid kickbacks to the nation's largest long-term care pharmacy, Omnicare.

Reassessments, respect spark antipsychotic-reduction success, providers told

By

Reducing the number of residents with dementia who are on antipsychotics starts with reassessment, experts advised at this week's American College of Health Care Administrators convocation In Orlando. The key is a multi-step process providers can follow.

Nursing home residents being treated successfully with Risperdal should stay on it, researchers recommend

Nursing home residents being treated successfully with Risperdal should stay on it, researchers recommend

By

Taking nursing home residents with dementia off of the antipsychotic drug Risperdal might do more harm than good, according to new research.

Risperdal settlement to cost J&J $181 million

The payouts will go to 36 states, plus the District of Columbia, which brought consumer fraud charges against Janssen for allegedly deceptively marketing the drug Risperdal to providers treating patients with Alzheimer's and dementia, Reuters reported.

J&J to pay $181 million for Risperdal settlement

J&J to pay $181 million for Risperdal settlement

By

Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.

Antipsychotics debate taken to new level

By

The battle over antipsychotics use for seniors and their marketing shows no signs of abating. The latest blow is a billion-dollar court decision against a pharmaceutical giant accused of too aggressively pushing the drug Risperdal, which is taken by many seniors with Alzheimer's disease.

Feds reject $1 billion Risperdal settlement offer

Government prosecutors rejected a $1 billion offer by Johnson & Johnson to settle a Risperdal case. Prosecutors alleged the antipsychotic medication was often prescribed off-label to treat aggressive behaviors of elderly nursing home residents with dementia. They are reportedly seeking a settlement closer to $1.4 billion. While doctors may prescribe drugs as they see fit, drug companies can market medications only for uses approved by the Food and Drug Administration.

Federal prosecutors reject $1 billion J & J settlement

By

Government prosecutors rejected a proposed settlement worth roughly $1 billion with pharmaceutical giant Johnson & Johnson over questionable marketing tactics for the antipsychotic Risperdal.

Latest Medicaid lawsuit settlement will cost J & J $158 million

Johnson & Johnson has agreed to pay $158 million to settle a Medicaid fraud lawsuit in Texas. The lawsuit accused J & J subsidiary Janssen Pharmaceuticals of giving state officials kickbacks in exchange for putting the antipsychotic Risperdal on an approved list for Medicaid recipients. The suit also claimed that Janssen marketed the drug as being safe and cost-effective, despite being linked to an increased risk of stroke and death in elderly dementia patients. Risperdal is approved only to treat adult schizophrenia. Johnson & Johnson was recently ordered to pay $327 million in South Carolina and $258 million in Louisiana in similar Rispedal lawsuits.

J & J pays $158 million to settle Texas Medicaid fraud lawsuit

J & J pays $158 million to settle Texas Medicaid fraud lawsuit

Johnson & Johnson has agreed to pay $158 million to settle a Medicaid fraud lawsuit. The lawsuit accused J & J subsidiary Janssen Pharmaceuticals of giving state officials kickbacks in exchange for putting the antipsychotic Risperdal on an approved list for Medicaid recipients.

Physician defends use of antipsychotics for dementia patients in nursing homes

In response to a recent report from the Office of the Inspector General, a prominent psychiatrist is defending the practice of prescribing antipsychotic medications for nursing home residents with dementia.

Report: Medicaid overspent on brand-name drugs

Report: Medicaid overspent on brand-name drugs

State Medicaid programs spent $329 million more than necessary by allowing certain prescriptions for brand-name drugs to be filled instead of generics in 2009, a conservative think tank said this week.

The verdict is in: Johnson & Johnson misled physicians in Risperdal marketing campaign

A jury in South Carolina on Tuesday found Johnson & Johnson's pharmaceutical unit, Ortho-McNeil-Janssen, guilty of misleading doctors about the safety and effectiveness of the anti-psychotic drug Risperdal.

Johnson & Johnson appeal denied, kickback case moves on in federal court

A federal judge has declined to dismiss a U.S. Justice Department lawsuit against Johnson & Johnson. The healthcare giant now will have to defend itself in court against allegations that it paid illegal kickbacks to influence sale of antipsychotics to nursing home residents.

Department of Justice files suit against Johnson & Johnson in connection with kickback scheme with Omnicare

Department of Justice files suit against Johnson & Johnson in connection with kickback scheme with Omnicare

The U.S. Department of Justice on Friday filed a lawsuit against Johnson & Johnson for its alleged role in a kickback scheme with Omnicare, the nation's largest long-term care pharmacy chain.